Literature DB >> 20580191

Reduction in narcotic use after primary total knee arthroplasty and association with patient pain relief and satisfaction.

Patricia D Franklin1, John A Karbassi, Wenjun Li, Wenyun Yang, David C Ayers.   

Abstract

We examined the prevalence of narcotic use before and after total knee arthroplasty (TKA) and its association with post-TKA pain relief and satisfaction. Data on 6364 primary, unilateral TKA patients in a national registry were analyzed. Before TKA, 24% of patients were prescribed one form of narcotic. Of these, 14% reported continued narcotic use at 12 months after TKA, whereas the majority discontinued use. Only 3% of patients who did not use narcotics before TKA had a narcotics prescription at 12 months. Patients who used narcotics before TKA were more likely to have a narcotic prescription at 12 months post-TKA, reported greater pain at 12 months, and were more likely to be dissatisfied with TKA outcome. These findings have implications for patient pre-TKA counseling. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580191     DOI: 10.1016/j.arth.2010.05.003

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  46 in total

1.  Meeting patient expectations and ensuring satisfaction in total knee arthroplasty.

Authors:  Hamid Rahmatullah Bin Abd Razak; Seng Jin Yeo
Journal:  Ann Transl Med       Date:  2015-11

2.  Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty.

Authors:  Jasvinder A Singh; David G Lewallen
Journal:  Rheumatology (Oxford)       Date:  2014-01-22       Impact factor: 7.580

3.  American Society for Enhanced Recovery and Perioperative Quality Initiative-4 Joint Consensus Statement on Persistent Postoperative Opioid Use: Definition, Incidence, Risk Factors, and Health Care System Initiatives.

Authors:  Michael L Kent; Robert W Hurley; Gary M Oderda; Debra B Gordon; Eric Sun; Monty Mythen; Timothy E Miller; Andrew D Shaw; Tong J Gan; Julie K M Thacker; Matthew D McEvoy
Journal:  Anesth Analg       Date:  2019-08       Impact factor: 5.108

4.  Preoperative opioid strength may not affect outcomes of anterior cervical procedures: a post hoc analysis of 2 prospective, randomized trials.

Authors:  Michael P Kelly; Paul A Anderson; Rick C Sasso; K Daniel Riew
Journal:  J Neurosurg Spine       Date:  2015-07-03

5.  Prevalence and risk factors for prolonged opioid use after total joint arthroplasty: a systematic review, meta-analysis, and meta-regression.

Authors:  Limin Wu; Mingyang Li; Yi Zeng; Haibo Si; Yuan Liu; Peng Yang; Bin Shen
Journal:  Arch Orthop Trauma Surg       Date:  2020-05-28       Impact factor: 3.067

6.  High-Risk Prescribing Increases Rates of New Persistent Opioid Use in Total Hip Arthroplasty Patients.

Authors:  Lia D Delaney; Vidhya Gunaseelan; Heidi Rieck; James Michael Dupree; Brian R Hallstrom; Jennifer F Waljee
Journal:  J Arthroplasty       Date:  2020-04-14       Impact factor: 4.757

Review 7.  Complexities of Perioperative Pain Management in Orthopedic Trauma.

Authors:  Daniel H Wiznia; Theodore Zaki; Michael P Leslie; Thomas M Halaszynski
Journal:  Curr Pain Headache Rep       Date:  2018-07-10

8.  Opioid use after fracture surgery correlates with pain intensity and satisfaction with pain relief.

Authors:  Arjan G J Bot; Stijn Bekkers; Paul M Arnstein; R Malcolm Smith; David Ring
Journal:  Clin Orthop Relat Res       Date:  2014-04-29       Impact factor: 4.176

9.  Patterns and predictors of persistent opioid use following hip or knee arthroplasty.

Authors:  S C Kim; N Choudhry; J M Franklin; K Bykov; M Eikermann; J Lii; M A Fischer; B T Bateman
Journal:  Osteoarthritis Cartilage       Date:  2017-04-19       Impact factor: 6.576

10.  Opioid use prior to total hip arthroplasty leads to worse clinical outcomes.

Authors:  Robert Pivec; Kimona Issa; Qais Naziri; Bhaveen H Kapadia; Peter M Bonutti; Michael A Mont
Journal:  Int Orthop       Date:  2014-02-27       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.